Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly and Company is conducting a clinical study titled FORAGER-1: A Phase 1, Open-Label, Multicenter Study of LOXO-435 (LY3866288) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer With FGFR3 Alterations. The study aims to assess the safety, side effects, and effectiveness of LOXO-435, either alone or in combination with other cancer treatments, in patients with FGFR3 gene alterations. This research is significant as it explores potential new treatments for advanced cancers.
The study tests LOXO-435, an oral drug, both as a standalone treatment and in combination with pembrolizumab and enfortumab vedotin, which are administered intravenously. These interventions target cancers with FGFR3 gene changes, aiming to improve patient outcomes.
This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning both researchers and participants know which treatments are being administered. The primary purpose is treatment-focused, aiming to determine the optimal dosage and assess the drug’s efficacy and safety.
The study began on January 12, 2023, with a primary completion date yet to be announced. The last update was submitted on July 18, 2025. These dates are crucial for tracking progress and anticipating results that could influence treatment options and market dynamics.
For investors, this study’s progress could impact Eli Lilly’s stock performance, especially if LOXO-435 shows promising results. Success in this study might enhance Eli Lilly’s competitive edge in the oncology market, potentially affecting investor sentiment positively.
The FORAGER-1 study is ongoing, with further details available on the ClinicalTrials portal.